Chronic Pain Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Biosplice Therapeutics, Sorrento Therapeutics, Amplo Pharma Novartis, Eli Lilly

DelveInsight’s “Chronic Pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Pain, historical and forecasted epidemiology as well as the Chronic Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Pain Market Forecast

Some of the key facts of the Chronic Pain Market Report: 

• The Chronic Pain market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The overall number of prevalent cases of chronic pain in the United States was 53,215,555 in 2021, and this figure is projected to rise between 2019 and 2032
• In the EU-5 countries, there were 93,000,660 instances of Chronic Pain overall in 2021, and this number is anticipated to rise from 2019 to 2032
• In January 2021, Abbott Laboratories has announced the release of NeuroSphere myPath, a digital health application designed to track and account for the patient’s impression of pain reduction and general health in relation to spinal cord stimulation (SCS) or dorsal root ganglion therapy (DRG)
• According to estimates from the Centres for Disease Control and Prevention (CDC), as of September 2018, there were 50.0 million US people with chronic pain (20.4%) and 19.6 million adults with high-impact chronic pain (8.0%)
• According to data from the National Health Interview Survey (NHIS) for 2019, 7.4% of people who had high impact chronic pain—chronic pain that frequently restricts daily living or employment activities—in the previous three months, while 20.4% of adults reported having chronic pain
• Key Chronic Pain Companies: Biosplice Therapeutics, Sorrento Therapeutics, Amplo Pharmaceuticals, Novartis, Eli Lilly and Company, Grünenthal GmbH, Taiwan Liposome Company, Centrexion Therapeutics, Biogen, Gruenthal and Mesoblast, Eli Lilly and Company, NEMA Research, Inc., Mundipharma, Janssen Pharma, Johnson & Johnson, Solvay Pharmaceuticals, Purdue Pharma LP, MedVadis Research Corporation, Bausch Health, Braeburn Pharma, Teva Branded Pharma, Mallinckrodt, and others
• Key Chronic Pain Therapies: Lorecivivint (SM04690), Resiniferatoxin (RTX), Ampion, SAF312, LY3857210, Tapentadol, TLC599, CNTX-4975, BIIB074 (Vixotrigine), Rexlemestrocel (MPC-06-ID), LY3016859, Hydrocodone, Oxycodone/naloxone, Fentanyl, Durogesic®, Marinol (dronabinol), Buprenorphine, Oxymorphone ER, tramadol ER, CAM2038, Hydrocodone ER, OROS hydromorphone, and others
• The Chronic Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Pain pipeline products will significantly revolutionize the Chronic Pain market dynamics.

Chronic Pain Overview

Typically, a patient with chronic pain is not diagnosed until three to six months of consistent discomfort have passed. In addition to reviewing symptoms and medical history, diagnosis frequently entails a battery of tests and procedures. Depending on the location and the cause of the pain, as well as other symptoms, the doctor will do several tests.

Get a Free sample for the Chronic Pain Market Report 

https://www.delveinsight.com/report-store/chronic-pain-market

Chronic Pain Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Pain Epidemiology Segmentation:

The Chronic Pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Chronic Pain
• Prevalent Cases of Chronic Pain by severity
• Gender-specific Prevalence of Chronic Pain
• Diagnosed Cases of Episodic and Chronic Chronic Pain

Download the report to understand which factors are driving Chronic Pain epidemiology trends @ Chronic Pain Epidemiology Forecast

Chronic Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Pain market or expected to get launched during the study period. The analysis covers Chronic Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Pain Therapies and Key Companies

• Lorecivivint (SM04690): Biosplice Therapeutics (formerly Samumed)
• Resiniferatoxin (RTX): Sorrento Therapeutics
• Ampion: Amplo Pharmaceuticals
• SAF312: Novartis
• LY3857210: Eli Lilly and Company
• Tapentadol: Grünenthal GmbH
• TLC599: Taiwan Liposome Company
• CNTX-4975: Centrexion Therapeutics
• BIIB074 (Vixotrigine): Biogen
• Rexlemestrocel (MPC-06-ID): Gruenthal and Mesoblast
• LY3016859: Eli Lilly and Company
• Hydrocodone: NEMA Research, Inc.
• Oxycodone/naloxone: Mundipharma
• Fentanyl: Janssen Pharma
• Durogesic®: Johnson & Johnson
• Marinol (dronabinol): Solvay Pharmaceuticals
• Buprenorphine: Purdue Pharma LP
• Oxymorphone ER: MedVadis Research Corporation
• tramadol ER: Bausch Health
• CAM2038: Braeburn Pharma
• Hydrocodone ER: Teva Branded Pharma
• OROS hydromorphone: Mallinckrodt

Discover more about therapies set to grab major Chronic Pain market share @ Chronic Pain Treatment Market

Chronic Pain Market Drivers

• Rich emerging pipeline
• Rise in awareness
• The upsurge in geriatric the population
• Increasing prevalence

Chronic Pain Market Barriers

• Drug Misuse and Addiction
• Lack of proper understanding
• Lack of reimbursement policies for Chronic Pain

Scope of the Chronic Pain Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Pain Companies: Biosplice Therapeutics, Sorrento Therapeutics, Amplo Pharmaceuticals, Novartis, Eli Lilly and Company, Grünenthal GmbH, Taiwan Liposome Company, Centrexion Therapeutics, Biogen, Gruenthal and Mesoblast, Eli Lilly and Company, NEMA Research, Inc., Mundipharma, Janssen Pharma, Johnson & Johnson, Solvay Pharmaceuticals, Purdue Pharma LP, MedVadis Research Corporation, Bausch Health, Braeburn Pharma, Teva Branded Pharma, Mallinckrodt, and others
• Key Chronic Pain Therapies: Lorecivivint (SM04690), Resiniferatoxin (RTX), Ampion, SAF312, LY3857210, Tapentadol, TLC599, CNTX-4975, BIIB074 (Vixotrigine), Rexlemestrocel (MPC-06-ID), LY3016859, Hydrocodone, Oxycodone/naloxone, Fentanyl, Durogesic®, Marinol (dronabinol), Buprenorphine, Oxymorphone ER, tramadol ER, CAM2038, Hydrocodone ER, OROS hydromorphone, and others
• Chronic Pain Therapeutic Assessment: Chronic Pain current marketed and Chronic Pain emerging therapies
• Chronic Pain Market Dynamics: Chronic Pain market drivers and Chronic Pain market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Chronic Pain Unmet Needs, KOL’s views, Analyst’s views, Chronic Pain Market Access and Reimbursement 

To know more about Chronic Pain companies working in the treatment market, visit @ Chronic Pain Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Chronic Pain Market Report Introduction

2. Executive Summary for Chronic Pain

3. SWOT analysis of Chronic Pain

4. Chronic Pain Patient Share (%) Overview at a Glance

5. Chronic Pain Market Overview at a Glance

6. Chronic Pain Disease Background and Overview

7. Chronic Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Pain 

9. Chronic Pain Current Treatment and Medical Practices

10. Chronic Pain Unmet Needs

11. Chronic Pain Emerging Therapies

12. Chronic Pain Market Outlook

13. Country-Wise Chronic Pain Market Analysis (2019–2032)

14. Chronic Pain Market Access and Reimbursement of Therapies

15. Chronic Pain Market Drivers

16. Chronic Pain Market Barriers

17.  Chronic Pain Appendix

18. Chronic Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services